SGMTEarnings•globenewswire•
Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Sentiment:Positive (70)
Summary
Denifanstat met all primary and secondary endpoints in Phase 3 clinical trial in moderate to severe acne conducted by license partner Ascletis in China
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 13, 2025 by globenewswire